Prognostic impact of PIK3CA mutation in stage IIIB or IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin

AbstractThe standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiotherapy (CCRT). Although the activated PI3-kinase/Akt pathway is known to be involved in both cisplatin-resistance and radioresistance, to date, only a few studies have reported significant as